论文部分内容阅读
目的探讨曲美布汀联合多塞平、培菲康治疗慢性胃肠功能紊乱的临床疗效。方法选取2015年3月—2016年3月巨野县章缝镇卫生院收治的慢性胃肠功能紊乱患者80例,随机分为观察组40例与对照组40例。对照组患者给予多塞平+培菲康+谷维素治疗,观察组患者给予曲美布汀+多塞平+培菲康治疗,比较两组临床疗效及不良反应发生情况。结果观察组总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论曲美布汀联合多塞平、培菲康治疗慢性胃肠功能紊乱的临床疗效确切,利于患者恢复和预后,且不良反应少。
Objective To investigate the clinical efficacy of trimebutine and docetaxel in the treatment of chronic gastrointestinal disorders. Methods From March 2015 to March 2016, 80 patients with chronic gastrointestinal dysfunction admitted to Zhangjia town hospital in Juye County were randomly divided into observation group (40 cases) and control group (40 cases). The patients in the control group were given doxepin + Pefikan + oryzanol, and the patients in the observation group were treated with trimebutine + doxepin + Pefikan. The clinical efficacy and adverse reactions of the two groups were compared. Results The total effective rate in the observation group was higher than that in the control group, with significant difference (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Trimebutine combined with doxepin and peifeffekang in the treatment of chronic gastrointestinal disorders is clinically effective and beneficial to the recovery and prognosis of patients with less adverse reactions.